These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34190510)

  • 1. Evaluation of response to tyrosine kinase inhibitors in renal cell carcinoma patients based on expression of miR-99b, -144, -210, -222, -302а and -377 in tumor tissue.
    Vitruk Yu V; Semko SL; Voylenko OA; Pikul MV; Borikun TV; Zadvornyi TV; Yalovenko TM; Stakhovsky EO; Rossylna OV
    Exp Oncol; 2021 Jun; 43(2):98-103. PubMed ID: 34190510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EXPRESSION OF miRNA AS PROGNOSTIC MARKERS OF RENAL CELL CARCINOMA COURSE.
    Vitruk Y; Borikun T; Rossylna O; Zadvornyi T; Semko S; Voylenko O; Stakhovsky O; Shipko A; Stakhovsky E
    Exp Oncol; 2022 Aug; 44(2):132-136. PubMed ID: 35964649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-99b-5p expression and response to tyrosine kinase inhibitor treatment in clear cell renal cell carcinoma patients.
    Lukamowicz-Rajska M; Mittmann C; Prummer M; Zhong Q; Bedke J; Hennenlotter J; Stenzl A; Mischo A; Bihr S; Schmidinger M; Vogl U; Blume I; Karlo C; Schraml P; Moch H
    Oncotarget; 2016 Nov; 7(48):78433-78447. PubMed ID: 27738339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arterial Spin Labeled Perfusion MRI for the Evaluation of Response to Tyrosine Kinase Inhibition Therapy in Metastatic Renal Cell Carcinoma.
    Tsai LL; Bhatt RS; Strob MF; Jegede OA; Sun MRM; Alsop DC; Catalano P; McDermott D; Robson PM; Atkins MB; Pedrosa I
    Radiology; 2021 Feb; 298(2):332-340. PubMed ID: 33258745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expressions of miR-96-5p, miR-29b-3p, and Their Target Gene THBS1 in Clear Cell Renal Cell Carcinoma and Sunitinib Resistance.
    Wu S; Wang Y
    Altern Ther Health Med; 2024 Jul; 30(7):268-273. PubMed ID: 37971460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Efficacy and Toxicity Profile of First-Line Sunitinib or Pazopanib in Metastatic Clear Cell Renal Cell Carcinoma in the Brazilian Population.
    Isaacsson Velho P; Nardo M; Souza MCLA; Bonadio RRCC; Marta GN; Muniz DQB; Bastos DA; Dzik C
    J Glob Oncol; 2018 Aug; 4():1-10. PubMed ID: 30199304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pilot Study on MicroRNAs as Biomarkers of Response to Sunitinib Treatment in Patients with Metastatic Renall Cell Carcinoma].
    Kováčová J; Juráček J; Poprach A; Büchler T; Kopecký J; Fiala O; Svoboda M; Lojová M; Slabý O
    Klin Onkol; 2018; 31(Supplementum1):161-162. PubMed ID: 29808694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Candidate MicroRNA Biomarkers of Therapeutic Response to Sunitinib in Metastatic Renal Cell Carcinoma: A Validation Study in Patients with Extremely Good and Poor Response.
    Kovacova J; Juracek J; Poprach A; Buchler T; Kopecky J; Fiala O; Svoboda M; Slaby O
    Anticancer Res; 2018 May; 38(5):2961-2965. PubMed ID: 29715124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive analysis of copy number variance and sensitivity to common targeted therapy in clear cell renal cell carcinoma: In silico analysis with in vitro validation.
    Li Y; Shen Y; Zhu Z; Wen H; Feng C
    Cancer Med; 2020 Aug; 9(16):6020-6029. PubMed ID: 32628820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-130b Promotes Sunitinib Resistance through Regulation of PTEN in Renal Cell Carcinoma.
    Sekino Y; Sakamoto N; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
    Oncology; 2019; 97(3):164-172. PubMed ID: 31195398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of miRNAs and Their Target Genes Associated with Sunitinib Resistance in Clear Cell Renal Cell Carcinoma Patients.
    Armesto M; Nemours S; Arestín M; Bernal I; Solano-Iturri JD; Manrique M; Basterretxea L; Larrinaga G; Angulo JC; Lecumberri D; Iturregui AM; López JI; Lawrie CH
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 38999991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma.
    Annala M; Nappi L; Azad AA; Mo F; Fazli L; Chi KN; Wyatt AW
    Clin Genitourin Cancer; 2017 Feb; 15(1):e145-e150. PubMed ID: 27324055
    [No Abstract]   [Full Text] [Related]  

  • 13. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma.
    Keisner SV; Shah SR
    Drugs; 2011 Mar; 71(4):443-54. PubMed ID: 21395357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma.
    Prior C; Perez-Gracia JL; Garcia-Donas J; Rodriguez-Antona C; Guruceaga E; Esteban E; Suarez C; Castellano D; del Alba AG; Lozano MD; Carles J; Climent MA; Arranz JA; Gallardo E; Puente J; Bellmunt J; Gurpide A; Lopez-Picazo JM; Hernandez AG; Mellado B; Martínez E; Moreno F; Font A; Calvo A
    PLoS One; 2014; 9(1):e86263. PubMed ID: 24475095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of spindle and kinetochore-associated protein 1 by antitumor miR-10a-5p in renal cell carcinoma.
    Arai T; Okato A; Kojima S; Idichi T; Koshizuka K; Kurozumi A; Kato M; Yamazaki K; Ishida Y; Naya Y; Ichikawa T; Seki N
    Cancer Sci; 2017 Oct; 108(10):2088-2101. PubMed ID: 28746769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.
    Choueiri TK; Fay AP; Gagnon R; Lin Y; Bahamon B; Brown V; Rosenberg JE; Hutson TE; Baker-Neblett KL; Carpenter C; Liu Y; Pandite L; Signoretti S
    Clin Cancer Res; 2013 Sep; 19(18):5218-26. PubMed ID: 23881929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma.
    Wood CG; Ferguson JE; Parker JS; Moore DT; Whisenant JG; Maygarden SJ; Wallen EM; Kim WY; Milowsky MI; Beckermann KE; Davis NB; Haake SM; Karam JA; Bortone DS; Vincent BG; Powles T; Rathmell WK
    JCI Insight; 2020 Nov; 5(22):. PubMed ID: 33208553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNAs as predictive biomarkers of response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma.
    Kovacova J; Poprach A; Buchler T; Cho WC; Slaby O
    Clin Chem Lab Med; 2018 Aug; 56(9):1426-1431. PubMed ID: 29451857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
    Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
    Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
    Vogelzang NJ; Pal SK; Ghate SR; Swallow E; Li N; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
    Adv Ther; 2017 Nov; 34(11):2452-2465. PubMed ID: 29076108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.